Suppr超能文献

LINC01287 通过 miR-298/MYB 调控肝细胞癌的发生发展和侵袭。

LINC01287 regulates tumorigenesis and invasion via miR-298/MYB in hepatocellular carcinoma.

机构信息

Department of Hepatobiliary Surgery, Gaozhou People's Hospital, Gaozhou, China.

Department of General Surgery, The First Affiliated Hospital of BaoTou Medical University, Inner Mongolia, China.

出版信息

J Cell Mol Med. 2018 Nov;22(11):5477-5485. doi: 10.1111/jcmm.13818. Epub 2018 Aug 22.

Abstract

Recently, it was reported that long non-coding RNAs (lncRNAs) participated in promoting hepatocellular carcinoma (HCC) initiation and progression. Herein, we reported that the expression level of LINC01287 was elevated in HCC cell lines and tissues. LINC01287 down-regulation inhibited HCC cells growth and invasion both in vitro and in vivo. LINC01287 exerted as a ceRNA and negatively regulated miR-298 expression. MYB was identified as a downstream target of miR-298. The miR-298/MYB axis mediated LINC01287's effect on HCC. To the best of our knowledge, our findings provided the first evidence that LINC01287 functioned as an oncogene in HCC. LINC01287 may be a candidate prognostic biomarker and a target for new therapies in HCC patients.

摘要

最近有报道称,长非编码 RNA(lncRNAs)参与促进肝细胞癌(HCC)的发生和发展。在此,我们报道了 LINC01287 在 HCC 细胞系和组织中的表达水平升高。LINC01287 的下调抑制了 HCC 细胞在体外和体内的生长和侵袭。LINC01287 作为 ceRNA,负调控 miR-298 的表达。MYB 被鉴定为 miR-298 的下游靶基因。miR-298/MYB 轴介导了 LINC01287 对 HCC 的影响。据我们所知,我们的研究结果首次提供了证据,表明 LINC01287 在 HCC 中作为癌基因发挥作用。LINC01287 可能是 HCC 患者的候选预后生物标志物和新治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e0/6201358/12d408ed16c4/JCMM-22-5477-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验